Related Experiment Video
Updated: Jun 16, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Development of a quantitative model of pregnane X receptor (PXR) mediated xenobiotic metabolizing enzyme induction
Nicholas S Luke1, Michael J DeVito, Imran Shah
1Department of Mathematics, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA. luke@ncat.edu
Abstract:
The pregnane X receptor plays an integral role in the regulation of hepatic metabolism. It has been shown to regulate CYP3A4, which is the most abundant cytochrome P450 in the human liver. With its large and flexible ligand-binding domain, PXR can be activated by an enormous range of relatively small, hydrophobic, exogenous compounds. Upon activation, PXR partners with the retinoid X receptor (RXR) to form a heterodimer. The newly formed heterodimer binds to an appropriate DNA response element, causing increased transcription. This leads to an induction in the level of CYP3A4. These mechanistic steps are included into a biologically-based mathematical model. The quantitative model predicts fold level inductions of CYP3A4 mRNA and protein in response to PXR activation. Model parameter values have been taken from literature when appropriate. Unknown parameter values are estimated by optimizing the model results to published in vivo and in vitro data sets. A sensitivity analysis is performed to evaluate the model structure and identify future data needs which would be critical to revising the model.
Related Concept Videos
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Drug Metabolism: Phase I Reactions
Quantitative Aspects of Drug-Receptor Interaction
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes